Kevin Hess, MD
Psychiatry · Eau Claire, WINPI 1427004126
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,350 of the $27,509 with a category attached, or 77.6%. AbbVie accounts for 90.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $21,629 and has fallen 99.4% since, to $131 in 2025. Among psychiatry clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $283.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Neuronetics, Inc.$1K
- Neurocrine Biosciences, Inc.$282
- Teva Pharmaceuticals USA, Inc.$271
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$264
- Otsuka America Pharmaceutical, Inc.$241
- plus $470 from 4 others
What the payments were for
- Speaking & faculty fees$21,35078%
- Travel & lodging$2,72310%
- Food & beverage$3,13611%
- Education$2991%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $24,892 |
| Neuronetics, Inc. | 12 | $1,089 |
| Neurocrine Biosciences, Inc. | 9 | $282 |
| Teva Pharmaceuticals USA, Inc. | 5 | $271 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $264 |
| Otsuka America Pharmaceutical, Inc. | 6 | $241 |
| Alkermes, Inc. | 4 | $174 |
| Vanda Pharmaceuticals Inc. | 2 | $143 |
| AstraZeneca | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$24,110
- NEUROSTAR TMS THERAPY SYSTEM$735
- FARXIGA$125
- Fanapt$119
How this compares
$27,509 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 28 | $238,923 |
| Austedo XrDeutetrabenazine | 28 | $152,683 |
| Invega SustennaPaliperidone Palmitate | 24 | $83,487 |
| VraylarCariprazine Hcl | 33 | $54,262 |
| RexultiBrexpiprazole | 31 | $45,063 |
| Paliperidone ErPaliperidone | 37 | $7,331 |
| Clozapine | 34 | $4,965 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $4,559 |
| Perphenazine | 45 | $3,894 |
| Methylphenidate Er (La)Methylphenidate Hcl | 12 | $3,051 |
| Aripiprazole | 63 | $2,893 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 52 | $2,509 |
| Quetiapine Fumarate | 149 | $2,236 |
| Clomipramine Hcl | 39 | $2,139 |
| Clonazepam | 203 | $2,093 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $271 | $152,68328 claims |
| AbbVieVraylar | $24,892 | $54,26233 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $241 | $45,06331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.
Other psychiatry in Eau Claire
- Scott WienerGreenfield$1.4M
- Joseph BergsRacine$346K
- Royle EenigenburgJuneau$344K
- Thomas IlicMilwaukee$324K
- Jay WinstonMilwaukee$238K
- Joseph BurgarinoMilwaukee$111K
- Sobia Kirmani MoeMadison$104K
- Jacob BehrensMilwaukee$94K
- Ned KalinMadison$48K
- Kenneth HerrmannMadison$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.